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The limitations in absorption of drugs with narrow absorption window, or those unstable in the intestinal 
pH or those exhibiting low solubility at high pH are primary candidates for gastroretentive drug delivery 
systems (GRDDS). The delivery system has been widely explored for its commercial potential for a wide 
variety of therapeutic agents. GRDDS offer clinical therapeutics for acute and chronic management. 
Hypertension is a chronic disease that requires long term treatment and its management by patient 
compliant dosage forms would be clinically useful. Antihypertensives belonging to different classes have 
proved good candidates for the formulation of GRDDS. The review aims to discuss various GRDDS 
researched for antihypertensive drugs to increase the gastric residing time, bioavailability, henceforth 
to reduce the dose of the drug, dosing frequency and increase patient compliance. It also explores 
various marketed products and the patents filed/granted for GRRDS of antihypertensives. The GRDDS 
investigated include effervescent and non-effervescent floating drug delivery systems, swelling and 
expanding systems and bio/mucoadhesive systems. Many other systems that provided research platforms 
include high density systems, raft forming systems and osmotic delivery systems. In clinical context, 
wherein combination of antihypertensives is indicated, dual release delivery systems may also be explored.
Keywords: Antihypertensive drugs. Gastroretention delivery systems/absorption. Floating systems. 
Expanding and swelling systems, Bio/mucoadhesive systems.
INTRODUCTION
The drug delivery systems for oral administration 
such as drug release rate-controlled delivery systems, 
time-controlled delivery systems and site-specific delivery 
systems have been extensively explored due to their 
significant therapeutic advantages. The current controlled 
release technology has made it possible to release drugs at 
a constant release rate for longer periods of time ranging 
from days to years (Sato et al., 2003; Streubel, Siepmann, 
Bodmeier, 2006). However, this benefit has not satisfied 
a variety of important drugs that (i) are locally active 
in the stomach, (ii) have an absorption window in the 
stomach or in the upper small intestine, (iii) are unstable 
in the intestinal or colonic environment, and/ (iv) exhibit 
low solubilities at high pH values (Streubel, Siepmann, 
Bodmeier, 2006; Rocca, Omidian, Shah, 2003). These 
limitations promoted the development of gastroretentive 
drug delivery systems (GRDDSs). Besides being able 
to continually and sustainably deliver drugs to the small 
intestinal absorption window, the improvements provided 
by GRDDSs include: achieving a greater and prolonged 
therapeutic effect and thus reducing the frequency of 
administration periods, providing a more effective 
treatment of local stomach disorders, and minimizing 
both lower-tract inactivation of the drug and drug effects 
on the lower intestinal flora (Sarojini, Manavalan, 2012). 
The prolongation of gastric residing time is expected 
to maximize drug absorption from GRDDSs due to 
increased dissolution of drug and prolonged residence in 
the gastric region. Prolonged gastric retention improves 
bioavailability, increases the duration of drug release, 
reduces drug waste, and improves the drug solubility 
of those that are less soluble in a high pH environment. 
Various approaches have been followed to encourage 
gastric retention of an oral dosage form. Floating systems 
have low bulk density so that they can float on the gastric 
juices in the stomach. The problem arises when the 
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stomach is completely emptied of gastric fluid. In such a 
situation, there is nothing to float on. A prolonged stay in 
the stomach is not desirable for drugs that (i) cause gastric 
lesions (e.g., NSAIDs); (ii) are unstable in the acidic pH 
of the stomach; or (iii) undergo a significant first-pass 
effect (i.e., metabolism in the liver prior to entering the 
systemic circulation; e.g., nifedipine) (Streubel, Siepmann, 
Bodmeier, 2006).
Different techniques used for gastric retention 
(Arora et al., 2005; Prinderre, Sauzet, Fuxen, 2011; 
Adebisi, Conway, 2011) are compiled as a schematic chart 
(Figure 1). These systems have been researched for a wide 
variety of therapeutic categories including antiulcer drugs, 
antibiotics, anti-diabetic drugs, cardiovascular drugs, 
drugs for gout and NSAIDS.
Hypertension and its therapy
Hypertension is the term used to describe high blood 
pressure. Normal blood pressure is below 120/80 mmHg; 
blood pressure between 120/80 mmHg and 139/89 mmHg 
is called “pre-hypertension”, and a blood pressure of 
140/90 mmHg or above is considered high. An elevation 
of the systolic and/or diastolic blood pressure increases 
the risk of developing heart (cardiac) disease, kidney 
(renal) disease, hardening of the arteries (atherosclerosis 
or arteriosclerosis), eye damage, and stroke (brain 
damage). These complications of hypertension are often 
referred to as end-organ damage because damage of these 
organs is the result of chronic (long duration) high blood 
pressure. To nullify its impact, the diagnosis of high 
blood pressure is important so that efforts can be made 
to normalize blood pressure and prevent complications 
(MedlinePlus, 2015; Macgill, 2016). The treatment 
approaches include diuretics, ACE inhibitors, angiotensin 
antagonists, β-adrenergic blockers, α-adrenergic blockers, 
calcium channel blockers and vasodilators (Table I). Most 
anti-hypertensive medications can be used either alone 
or in combination: some are used only in combination 
(amlodipine with lisinopril); some are preferred over 
others in certain specific medical situations; and some 
are not to be used (contraindicated) in specific situations. 
Combination therapy is advocated when monotherapy 
fails or is not tolerated. In practice, a large majority of 
hypertensives ultimately require 2 or more drugs. Even 
initial treatment of mild to moderate hypertension with a 
low dose combination is being advocated as an alternative 
strategy. (Tripathi, 2003).
Need for GRDDS of antihypertensive drugs
Hypertension is one of the most common conditions 
in primary care and one of the key risk factors, along with 
hyperlipidemia, hyperglycemia, obesity and smoking 
etc that contribute to other diseases like myocardial 
infarction, stroke, renal failure and death. Joint National 
committee VIII (United States) estimates suggest more 
than 1 billion hypertensive patients world-wide. As per 
WHO report on World Health Statistics 2012, one in 
every three adults has raised blood pressure (Arora et 
FIGURE 1 - General approaches to gastric retention.
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al., 2015). This becoming a chronic disease requires 
long term treatment. GRDDS can be a viable option for 
management of hypertension management as several 
antihypertensive drugs are associated with (a) narrow 
absorption window {e.g. furosemide (Pawar et al., 2012; 
Davis, 2005; Darandale, Vavia, 2012), atenolol, diltiazem 
(Srikanth et al., 2011)}; (b) short half-life {e.g. losartan 
(Chen et al., 2010), furosemide (Darandale, Vavia, 
2012)}, (c) instability {e.g. captopril (Streubel, Siepmann, 
Bodmeier, 2006; Pawar et al., 2012)} at high pH values; 
(d) low solubility {e.g. verapamil (Streubel, Siepmann, 
Bodmeier, 2006; Niranjanbhai et al., 2012), furosemide 
(Streubel, Siepmann, Bodmeier, 2006), propranolol 
(Chinta et al., 2009)} at high pH, and (e) degradation in the 
colon {e.g. metoprolol (Srikanth et al., 2011)}. GRDDS 
is an approach to prolong gastric residence time, thereby 
targeting site specific drug release in the upper GIT for 
local or systemic effects. This site-specific drug delivery 
reduces undesirable side effects of administered drug as 
it can minimize the counter activity of the body leading to 
higher drug efficiency. This review aims to discuss various 
GRDDS of antihypertensive drugs to increase the gastric 
residence time, bioavailability, henceforth to reduce the 
dose of the drug, dosing frequency and increased patient 
compliance. 
GRDDS FOR ANTIHYPERTENSIVE DRUGS
Gastroretentive systems using polymers have been 
extensively investigated for various antihypertensive 
drugs and the findings are summarized in a classified 
manner in the following sections. 
Floating Systems
Effervescent systems
Floatability can be achieved by generation of gas 
bubbles. CO2 can be generated in situ by incorporation 
of carbonates or bicarbonates, which react with acid-
either the natural gastric acid or co-formulated as citric or 
tartaric acid. An alternative is to incorporate a matrix with 
entrapped liquid, which forms a gas at body temperature. 
Drug and excipients can be formulated independently and 
the gas generating unit can be incorporated into any of the 
layers. Further refinements involve coating the matrix with 
a polymer which is permeable to water, but not to CO2. 
The main difficulty of such formulation is to find a good 
compromise between elasticity, plasticity and permeability 
of the polymer (Bardonnet et al., 2006).
Chen et al. (2010) formulated gastroretentive 
tablets based on effervescence/swelling mechanism using 
polymers sodium carboxymethyl cellulose, hydroxyethyl 
cellulose and sodium bicarbonate for losartan. To evaluate 
swelling and effervescent properties, tablets were prepared 
with different compression pressure. The optimized 
formulation floated for more than 16 h with a swollen 
diameter of 2 cm within 3 h in the simulated gastric 
fluid. Also, the formulations showed pH-dependent drug 
release with an extension for 24 h. Clinical trials of the 
optimized GRDDS were assessed on the bioavailability 
of losartan and the formation extent of active metabolite 
E3174 by CYP2C9 polymorphism. Trials in healthy 
human volunteers showed an enhanced bioavailability 
of approximately 164% as compared to the immediate 
release marketed formulation Cozaar®. As expected, the 
developed GRDDS showed favourable pharmacokinetic 
parameters: increased mean residence time whereas, Tmax 
TABLE I - The commercial dosage forms of antihypertensive 
drugs
Category Drug Dosage forms
Diuretics 
       Thiazides 
        
       Loop acting 
 
       K+ sparing 
       drugs 
 
Hydrochlorthiazide, 
Chlorthalidone 
Furosemide, 
Terosemide 
Spironolactone, 
Triamterene
 
Tablets 
Tablets 
Tablets, injection 
Tablets 
Tablets 
Tablets
ACE inhibitors Captopril, 
Enalapril, 
Lisinopril 
Quinapril
Tablets 
Tablets 
Tablets 
Tablets
Angiotensin 
antagonist
Losartan, 
Candesartan
Tablets 
Tablets
β-adrenergic 
blockers
Propranolol, 
Metoprolol, 
Atenolol
Tablets, injection 
Tablets, injection 
Tablets
α-adrenergic 
blockers
Prazosin, 
Terazosin
Tablets 
Tablets
β + α Adrenergic 
blockers
Labetalol, 
Carvedilol
Tablets, injection 
Tablets
Calcium 
Channel 
Blockers
Nifedipine, 
Felodipine, 
Amlodipine 
Nicardipine, 
Verapamil, 
Diltiazem, 
Nitrendipine
Tablets, Capsules 
Tablets 
Tablets 
Capsules, injection 
Tablets, injection 
Tablets, injection 
Tablets, injection
Vasodilators Hydralazine, 
Minoxidil,
Tablets, injection 
Lotion, Solution, 
spray
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and Cmax were lower as compared to Cozaar® concluding 
the enhancement in bioavailability due to gastroretention.
Ozdemir, Ordu and Ozkan (2000) designed floating 
bilayer tablets with controlled release for furosemide. To 
enhance the poor solubility of furosemide in the gastric 
medium, its inclusion complex with beta-cyclodextrin in 
a 1:1 proportion was prepared by kneading method. The 
first layer constituted of HPMC 4000, HPMC 100, and 
CMC and the drug. The second layer was composed of 
the effervescent mixture of sodium bicarbonate and citric 
acid. The in vitro floating studies inferred that lesser the 
compression force the shorter was the time of onset of 
floating. For tablets compressed at 15 MPa, floatation 
was initiated in 20 min whereas at a force of 32 MPa 
the time was prolonged to 45 min. In vivo studies on six 
healthy male volunteers revealed gastroretention of 6h 
when monitored by radiography. Pharmacokinetic studies 
showed that the bioavailability of the drug from the 
floating tablets was 1.8 times than that of the conventional 
tablets. These findings suggested that the delivery of 
furosemide from floating bilayer tablets resulted in 
sustained antihypertensive effect. 
Another study on furosemide, by Meka et al. (2009) 
reports formulation of polymer coated mini tablets as 
multiple unit gastroretentive floating systems. A core 
containing a solid dispersion of furosemide in polyvinyl 
pyrrolidone with other excipients was prepared by 
direct compression. The core was coated first with an 
effervescent layer (sodium bicarbonate) and a second 
coat with polymethacrylates (Eudragit RL30D) was 
affected. Interestingly, with an increase in the amount of 
the effervescent agent and decrease in the coating level of 
the polymer, the time to float was decreased. The in vivo 
gastric residence time examined by radiograms revealed 
gastroretention of about 6 h that would be helpful in drug 
release sustainment. The stability samples showed no 
significant change in dissolution profiles.
In a research endeavour, Elkheshen, Yassin and 
Alsuwayeh (2004) formulated and evaluated floating 
effervescent sustained release tablets of verapamil 
hydrochloride from granules containing mixtures of a 
forming matrix (HPMC, HPC, EC/carbopol) together 
with sodium bicarbonate and anhydrous citric acid. In 
vivo X-ray imaging experiments conducted on fasted 
beagle dogs to abolish the effect of food, showed that the 
gastric emptying time of the floating tablets could be more 
than 4 h and less than 5 h. Results demonstrated that the 
optimized formulation delayed the gastric emptying time 
under fasted conditions. While fed state is the primary 
requirement for gastroretention in vivo studies so the fed 
state would prove useful.
Directly compressed floating tablets of verapamil 
hydrochloride have also been reported by Dawange, 
Khadabadi and Saboo (2015). A variety of polymers and 
effervescent properties (HPMC K15M, sodium alginate, 
sodium bicarbonate and citric acid) were utilized to 
optimize the desired disposition profile by 32 factorial 
design. It was found that the levels of HPMC K4M, 
sodium alginate and their interaction had significant 
influence on both the drug release and floating lag time of 
the delivery system. In vitro drug release studies showed 
sustained release for 12 h and that followed Korsemeyer 
Peppas model.
A similar formulation approach was used by 
Rahman, Ali and Khar (2006) for formulating a bilayer 
floating tablet of captopril using direct compression 
technology. First layer consisted of HPMC K-grade and 
a mixture of citric acid and sodium bicarbonate. Second 
layer contained captopril and various polymers like HPMC 
K15M, PVP-K30 and Carbopol 934P. The optimized 
formulation released 95% of drug in 24 h in vitro, while the 
floating lag time was 10 min and the formulation remained 
floatable throughout the study. The release kinetics 
followed the Higuchi model. X-ray imaging method 
used to evaluate the buoyancy behaviour of captopril 
bilayer-floating tablet in 10 human subjects showed that 
the tablets remained in the stomach for about 6.4 h. Thus, 
the optimized formulation showed gastroretention due 
to buoyancy conferred by the porous structure formed 
due to entrapment of CO2. In a mechanistic study, 
Martinez, Ramirez and Robles (2010) studied the effect 
of antioxidant metolose SH 4000 SR on drug release from 
floating matrix tablets of captopril. It was concluded that 
the higher levels of gas forming agent caused hindrance 
on drug release, as carbon dioxide bubbles obstructed the 
diffusion path and decreased the matrix coherence. The 
developed dosage form remained buoyant for a period 
of more than 8 h. An increase in polymer concentration 
resulted in decreased drug release rate due to an increasing 
tortuosity and length of the diffusion path through the 
matrix. 
Barmpalexis, Kachrimanis and Georgarakis (2011) 
developed an effervescent controlled release floating 
tablets of nimodipine-PEG solid dispersions. The mixture 
proportions of PEG, HPMC, PVP, effervescent agents and 
nimodipine were optimized in relation to drug release (t 
60% min and t90%) and floating properties (tablet’s floating 
strength and duration), employing a 25-run D-optimal 
mixture design combined with artificial neural networks 
and genetic programming. Results showed that nimodipine 
existed as mod I microcrystals in the solid dispersions and 
was stable for at least a three-month period. The tablets 
GRDDS for antihypertensive therapy
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showed good floating properties and controlled release 
profiles, with drug release proceeding via swelling and 
erosion of the polymer matrix. The floatation duration 
varied from 1 to 20 h with a lag time of less than 3 min. 
The researchers concluded enhancement in solubility and 
gastroretention to improve site specific bioavailability of 
the drug.
Apart from research reports on tablets, the literature 
also cites gastroretentive capsules of antihypertensive 
drugs. Moursy et al. (2003) formulated sustained release 
floating capsules of nicardipine HCl. A hydrocolloid of 
high viscosity grade was used for the floating systems, 
and for aiding buoyancy sodium bicarbonate was added 
to allow evolution of CO2. In vitro evaluation showed an 
increase in floating duration with an increase in proportion 
of hydrocolloid. The optimized sustained release 
floating capsules were evaluated in vivo in comparison 
to MICARD (commercially available conventional 20 
mg capsule of nicardipine hydrochloride capsules) by 
using it on rabbits. Drug determination in rabbit plasma 
revealed a prolonged sustained drug release of 16 h over 
the conventional “MICARD” capsule (8 h).
Non-effervescent systems
This type of system, after swallowing, swells via 
imbibitions of gastric fluid to an extent that prevents their 
exit from the stomach. The formulation methods of such 
type of dosage forms involve the mixing of the drug with 
a gel, which swells when it comes in contact with gastric 
fluid and maintains a relative integrity of shape and a bulk 
density of less than one within the outer gelatinous barrier. 
The air trapped by the swollen polymer provides buoyancy 
to these dosage forms (Sarojini, Manavalan, 2012).
In an attempt to develop non-effervescent GRDDS 
of antihypertensives, Sultana, Bhavna and Iqbal (2009) 
formulated gastroretentive microspheres of lacidipine 
using chitosan as polymer and glutaraldehyde as the 
cross-linking agent. The effect of independent variables 
such as concentration of polymer, glutaraldehyde volume, 
stirring speed and cross-linking time was evaluated on 
the dependent variables: mucoadhesion and entrapment 
efficiency using central composite design. It was found 
that the polymer concentration and glutaraldehyde volume 
had pronounced effect on dependent variables. 
Shimpi et al. (2004) explored the application of 
gelucire 43/01 for designing floating granules of a highly 
water-soluble drug diltiazem HCl. The granules were 
prepared by melt granulation technique and evaluated 
for pharmaceutical characteristics. The results of in vivo 
gamma-scintigraphy in healthy human volunteers showed 
that the granules retained in stomach for 6 h and 65–80% 
of drug was released over 6 h with an initial fast release 
from the surface. It was concluded that hydrophobic lipid, 
gelucire 43/01, can be considered as an effective carrier 
for design of a multi-unit floating drug delivery system of 
diltiazem HCl. Additionally, a polymer based multiunit 
floating system of diltiazem hydrochloride was developed 
by Ma et al. (2008). Floating alginate microspheres were 
developed by ionotropic gelation method using calcium 
carbonate as floatation aid. Experiments were conducted 
to enhance the drug encapsulation efficiency by adding 
chitosan into the gelation medium and the drug release 
was delayed by coating with Eudragit. Both uncoated 
and coated microspheres were able to continuously 
float over the simulated gastric fluid for 24 h in vitro. 
Gamma scintigraphy technique was used to compare 
gastrointestinal transit of optimized floating sustained 
release microspheres with that of the non-floating system 
manufactured from the same material, in healthy human 
volunteers. It was observed that the gastric-retention time 
of the optimized floating microspheres was prolonged for 
over 5h and was 2.5h for non-floating system. Alginate 
based floating beads of diltiazem HCl have also been 
reported by Saxena et al. (2016). The floating beads 
were prepared by ionotropic external gelation technique 
using CaCl2 as cross-linking agent. The authors however 
attempted to improve both the entrapment efficiency and 
drug release by incorporating low methoxy pectin and 
sunflower oil as co-polymers along with sodium alginate. 
SEM images of beads showed sponge like nature with 
little droplets of oil that imparted buoyancy to the beads. 
This report paves way for experimenting with many more 
biological macromolecules and low density food grade oils 
for preparation of floating beads.
In this context, Patel et al. (2006) formulated and 
evaluated floating chitosan microspheres of propranolol 
hydrochloride. Microspheres were prepared by chemical 
denaturation using glutaraldehyde as a cross-linking agent. 
A 32 full factorial design was used to study the effect of 
independent variables like drug: polymer ratio and volume 
of cross-linking agent on dependent variables, such as 
drug entrapment efficiency, floating lag time, T80%, particle 
size and similarity factor. In vivo study in healthy rabbits 
demonstrated sustained antihypertensive effect of floating 
microspheres of propranolol hydrochloride over a 12 h 
period due to slow release of the drug. In another research, 
Strubing, Metz and Mader (2008) prepared a single unit 
floating Kollidon SR matrix tablets of propranolol HCl 
and characterized it for the floating strength of tablets and 
the drug release profiles. The tablets remained buoyant for 
24 h with a very short lag time and the floating strength 
was inferred to be dependent upon the level of Kollidon 
A. Porwal, H. Dwivedi, K. Pathak
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SR and improved with high polymer/drug ratio. The 
drug release kinetics followed Fickian diffusion. While 
the results concluded the floating and sustained release 
properties, the viability of single unit system over the 
reported multiparticulate system is debatable especially 
in the absence of in vivo studies.
An interesting report by Chinta et al. (2009) explores 
a novel spray-dried tableting excipient made of chitosan 
(all three grades) and lactose for developing GRDDS 
of propranolol HCl. Specific amount(s) of chitosan 
was dissolved in an aqueous solution of citric acid and 
mixed with aqueous solution of lactose and the drug. The 
resultant solution was spray dried to get granules that 
were directly compressed with sodium bicarbonate. The 
tablets showed their 50% drug release between 30 and 
35 min. Another report on propranolol HCl by Porwal, 
Swami and Saraf (2011) describes preparation of sustained 
release microballoons for increasing its bioavailability by 
increasing gastroretention. Microballoons were prepared 
by the non-aqueous O/O emulsion solvent diffusion 
evaporation method using Eudragit RSPO as polymer. It 
was found that preparation temperature determined the 
formation of cavity inside the microballoon and this in turn 
determined the buoyancy. The microballoons presented 
spherical and smooth morphologies and remained buoyant 
for >12 h with favourable in vitro release characteristics. 
In vitro release kinetics followed Higuchi model mainly 
controlled by diffusion; and showed a biphasic pattern 
with an initial burst release, followed by sustained release 
for 12 h. A single unit floating system of propranolol HCl 
has also been described by Srikanth et al. (2012) Gastric 
floating tablet was developed by using central composite 
design and the effects of formulation variables on drug 
release and the buoyancy properties were investigated. 
The independent variables were polyethylene oxide 
WSR coagulant and sodium bicarbonate. Mathematical 
modelling of the responses demonstrated significant 
effects of independent variables on floating lag time, drug 
release at 1h and t90%. In vivo studies in human volunteers 
demonstrated buoyancy in gastric fluid and the gastric 
residence time was enhanced in the fed in comparison to 
the fasted state.
Poorly water soluble antihypertensive drugs have 
also been developed as non-effervescent GRDDS. 
Iannuccelli et al. (2000) used solid dispersion of 
furosemide inpolyvinylpyrrolidone (PVP) to prepare 
floating multiple unit system. The complete dose release 
over the actual intra-gastric residence time of the system 
(about 8 h) was achieved by loading both the core and the 
membrane forming the units with a 1:5 furosemide/PVP 
solid dispersion. XRD showed a decrease in crystallinity 
of furosemide in solid dispersion, which lead to the 
improved solubility and dissolution rate of the drug, that 
further led to desired release profile from the floating units. 
Further, Sahu, Singh and Verma (2011) formulated 
non-effervescent floating matrix tablets of furosemide 
using chitosan and HPMC. The tablets were evaluated 
for floating capability and in-vitro drug release kinetics. 
The drug release followed non-Fickian diffusion. On 
combining HPMC with chitosan in various mixtures, 
it was observed that formulations followed zero-order 
kinetics with floatation period of >8 h. 
ElMeshad and El-Ashmoony (2012) prepared 
buoyant beads enclosing furosemide by cross-linking 
chitosan with dioctyl sodium sulphosuccinate and 
characterized. The spherical beads floated for over 12 h 
in simulated gastric fluid and affected retarded release 
of the drug as compared to pure drug powder and Lasix 
tablets. The beads remained buoyant in the stomach of 
dogs for 6 h. The results concluded that chitosan floating 
beads as effective carrier for furosemide, maximizing its 
therapeutic effect at the site of absorption in a controlled 
release pattern.
In another research endeavour, Streubel, Siepmann 
and Bodmeier (2002; 2003; 2003a) prepared microparticles 
of verapamil containing polypropylene foam powder 
and different polymers (Eudragit RS, EC, polymethyl 
methacrylate) by o/w solvent evaporation method. They 
also formulated a monolithic floating drug delivery system 
based on highly porous polypropylene and matrix-forming 
polymers. The highly porous foam powder provided low 
density tablets which could float for at least 8 h in 0.1N 
HCl. Drug release characteristics were modified according 
to the ratio of matrix-forming polymer and foam powder 
and were also strongly related to drug chemistry.
Coated minitablets of the verapamil formulated by 
Sawicki (2002) were assessed for their in vivo performance 
in healthy human volunteers. An increase in AUC was 
observed for testing minitablet against the immediate 
release formulation. However, the results could not 
conclude the gastric retention because of the indirect 
link between pharmacokinetics and the gastrointestinal 
position.
In another study on verapamil, Eldeen, Alsara and 
Mohizea (2006) designed gastroretentive beads using 
chitosan as polymer and glutaraldehyde as a cross-
linking agent. Internal structure of dried beads confirmed 
encapsulation of verapamil into the bead cores. The beads 
prepared by using medium molecular weight chitosan 
showed good floating characteristics and floating lag 
time was found to be 5 min with total buoyancy duration 
of >6 h. The formulations exhibited a kinetic model of 
GRDDS for antihypertensive therapy
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combined mechanism(s) of diffusion, partially through 
a swollen matrix and partially through water-filled 
pores. Floating microspheres (251.80 to 350.75 µm) of 
verapamil HCl by solvent-diffusion evaporation method 
using cellulose acetate, Acrycoat S100 and Eudragit S100 
have been prepared by Tanwar, Naruka and Ojha (2008). 
The microspheres showed prolonged drug release and 
remained buoyant for more than 12 h that is nearly two 
times the value reported for gastroretentive beads reported 
by Eldeen et al. (2006). In vitro release study demonstrated 
non-Fickian diffusion of the drug and radiographic 
images of dog stomach revealed that cellulose acetate 
microspheres loaded with barium sulphate floated on the 
gastric fluid for about 3.2 h. The hollow structure of the 
microspheres was responsible for the floating properties.
A similar formulation approach was used by 
Soppimath et al. (2006) to study the effect of co-
excipients on drug release profile and floating property 
of the hollow microspheres of nifedipine. The drug was 
incorporated into cellulose acetate hollow microspheres 
prepared by solvent diffusion/evaporation technique in 
the presence of co-excipients like polyethylene glycol, 
dibutyl phthalate and poly(-caprolactone) by using ethyl 
acetate as a dispersing solvent. An increase in polymer 
concentration resulted in an increase in the size of the 
microspheres. The microspheres remained buoyant in 
simulated gastric fluid for over 12 h. The presence of 
co-excipients affected the buoyancy of the microspheres. 
The cellulose acetate-polyethylene glycol microspheres 
had lower buoyancy that increased with increasing 
concentration of polyethylene glycol (PEG). However, 
on increasing the PEG concentration from 10% to 40%, 
the buoyancy decreased from 51.3% to 11.8%. Better 
buoyancy (62–82%) was observed for microspheres 
made with water-insoluble plasticizer dibutyl phthalate 
due to its hydrophobic nature that prevented wetting as 
well as water uptake. The drug release was in a controlled 
manner that was amenable to modification by the process 
variables.
Floating gastroretentive microspheres of carvedilol 
using EC and HPMC have been reported by Zhang et al. 
(2016). The formulations were screened for drug loading 
(74.62±2.05 to 95.02±1.02%), particle size (270.04±10.30 
to 356.30±10.60 μm), floating time (4.5 to 9.12 h) and 
swelling at the end of 4h (67.25±1.67 to 93.64±3.05%). 
The in vitro drug release in pH 1.2 after 6 h was found in 
the range of 64.45±1.41 to 88.07± 1.74%. The optimized 
formulation (containing EC=1.0% and HPMC=0.5%) was 
significantly effective in promptly lowering the systolic 
blood pressure as compared to that of conventional tablet 
in hypertensive patients. 
Using a polymeric blend of hydroxyethylcellulose 
and chitosan, and sodium bicarbonate Chen et al. (2013) 
developed gastroretentive drug delivery systems of 
losartan by combining floating and swelling approaches. 
They found that formulations containing equivalent ratio 
of hydroxyethylcellulose and chitosan with 20 mg sodium 
bicarbonate began floating within 1 min and floated for 
more than 16 h, exhibiting a swelling ratio of 2 (due 
to polymeric blend) to achieve an adjustable sustained 
release profile. 
Similarly, Nur and Zhang (2000) designed captopril 
floating tablets using HPMC (4000 and 15000 cps) and 
Carbopol 934P. In vitro buoyancy studies exhibited that 
tablet with hardness of 2 kg/cm2, after immersion floated 
immediately whereas the tablets with hardness of 4 kg/
cm2 displayed a lag time of 3 to 4 min. Tablets in both 
cases remained floating for 24 h. No floating capability 
was found in the tablet with 8 kg/cm2 hardness. It was 
concluded that the buoyancy of the tablet is governed by 
both the swelling of the hydrocolloid particles on the tablet 
surface when it contacts the gastric fluids and the porosity 
of the tablets. A prolonged release for 24h from the floating 
tablets and the release kinetics fitted Korsemeyer and 
Peppas equation was followed by first order kinetics. 
In another research, Wu et al. (1997) prepared 
floating sustained release tablets of nimodipine using 
HPMC and PEG 6000. Before formulating floating 
tablets, nimodipine was incorporated into poloxamer-188 
solid dispersion after which it was directly compressed 
into floating tablets. Formulations were optimized using 
uniform design and variables affecting nimodipine release 
from matrix were studied. In vitro release followed zero-
order kinetics and it was observed that an increase in 
HPMC and decrease in the PEG 6000 content resulted 
in decrease in the in vitro release of nimodipine. In vivo 
studies in healthy volunteers showed that the optimized 
formulation could remain floating on gastric fluid for 
more than 10 h. Relative bioavailability of floating 
tablets was 391.46% and MRT was more than twice the 
conventional tablets. Thus, floating tablets of nimodipine 
loaded solid dispersion results in tremendous increase in 
the bioavailability of the drug.
Hydrophilic cellulose and pH-independent acrylic 
polymer based directly compressible controlled release 
floating matrix tablets of nicorandil were designed and 
developed by Nath and Ahmed (2016). The optimized 
formulation was evaluated for stability study and in vivo 
absorption in rabbits to compare the pharmacokinetic 
parameters with commercially available immediate release 
tablet of nicorandil. In vivo gamma scintigraphy studies 
revealed that the system was floated for a period of 6-7 h 
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in the stomach and in vivo absorption studies showed a 
significant increase in the AUC and MRT.
Expanding and swelling systems
A dosage form in the stomach will withstand 
gastric transit if it is bigger than the pyloric sphincter. 
However, the dosage form must be small enough to be 
swallowed, and must not cause gastric obstruction either 
singly or by accumulation. Thus, three configurations 
are required: a small configuration for oral intake, an 
expanded gastroretentive form and a final small form 
enabling evacuation following drug release. Unfoldable 
and swellable systems have been investigated. Unfoldable 
systems are made of biodegradable polymers. The idea 
is to make a carrier, such as a capsule, incorporating a 
compressed system that extends in the stomach. Swellable 
systems are also retained because of their mechanical 
properties. The swelling usually results from osmotic 
absorption of water. The dosage form is small enough 
to be swallowed, and swells in gastric liquids. The bulk 
enables gastric retention and maintains the stomach in a 
‘‘fed’’ state, suppressing housekeeper waves (Bardonnet 
et al., 2006).
Darandale and Vavia (2012) developed and 
characterized a gastroretentive dosage form suitable 
for controlled drug release of furosemide. It consists of 
a drug loaded polymeric film made up of a bilayer of 
immediate and controlled release layers which was then 
folded (zig-zag folding; Figure 2) into a hard gelatin 
capsule. The bilayer film consists of hydroxypropyl-β-
cyclodextrin in both layers and Carbopol ® 971P NF, 
Eudragit RLPO and HPMC E4M in the controlled release 
layer. The film was shown to unfold and swell under acidic 
conditions and provide immediate release of the drug for 
1h and controlled release for up to 12 h in acidic medium. 
Unfolding and swelling of the film and its bioadhesion to 
the gastric mucosa forms the key to gastroretention.
A similar approach was used by Sathish et al. (2013) 
for the preparation of a novel expandable gastroretentive 
dosage form based on an unfolding mechanism. They 
prepared a bilayer polymeric film of captopril folded into 
a hard gelatin capsule, which achieved gastric retention 
due to unfolding of the dosage form within 15-20 min. 
Films were formulated by solvent-casting technique using 
EC, HPMC E15 and Eudragit RLPO as polymers and 
dibutyl phthalate as the plasticizer in both the layers. Apart 
from routine technical parameters, the bilayer films were 
evaluated for unfolding behaviour based on the mechanical 
shape memory of polymers. The capsulated zigzag folded 
film was shown to unfold in the gastric juice and provided 
drug release up to 12 h in the simulated gastric fluid. The 
X-ray study revealed that the GRDDS was retained in the 
stomach for up to 6± 0.5 h in fasting condition and 8 h in 
fed state validating the design.
In an effort to design a controlled-release, expandable 
GRDDS; Biswas et al. (2014) fabricated a drug delivery 
system of carvedilol using HPMC and psyllium. Mass 
swelling ratios at equilibrium were higher for batches 
containing psyllium which rendered them buoyant in the 
simulated gastric fluid within 9 min and maintained the 
structural integrity for a maximum period of 23.8±0.97 
h. The batch with HPMC K15M and psyllium in the ratio 
2:1 exhibited Fickian type swelling mechanism. The drug 
diffused out through the gel barrier around the swollen 
matrix slowly via diffusion/relaxation controlled transport. 
Release retardant effect of psyllium was manifested in 
high values of t50% and t80% of 7.8 0.59 and 16.1±0.26 h, 
respectively, for the optimized batch. 
Bio/Mucoadhesive systems
They bind to the gastric epithelial cell surface, or 
mucin, and extend the GRT by increasing the intimacy 
and duration of contact between the dosage form and the 
biological membrane. The epithelial adhesive properties 
of mucin have been applied in the development of Gastro 
retentive drug delivery systems (Sarojini, Manavalan, 
2012).
Pathak, Mishra and Mishra (2013) developed 
gastroretentive mucoadhesive films of captopril by 
using polymers like EC, HPMC and carbopol 934P and 
glycerine(plasticizer) for treatment of hypertension. The 
release kinetics followed Korsmeyer-Peppas model. 
FIGURE 2 - Folding pattern of film for gastroretentive bilayer 
film of furosemide. (Darandale, Vavia, 2012.)
GRDDS for antihypertensive therapy
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The optimized formulation showed best mucoadhesive 
strength and a drug release of 99.06% at 24th hour. In 
another report on captopril; Pawar, Lalitha and Ruckmani 
(2015) prepared gastroretentive captopril loaded alginate 
beads by ionotropic gelation method using sodium 
alginate in combination with natural gums containing 
galactomannans (Senna tora seed gum, guar gum and 
locust bean gum) in the presence of calcium chloride. 
From the entrapment efficiency and drug release studies, 
it was concluded that galactomannans in combination 
with sodium alginate show sustained release property. 
The optimized formulation showed satisfactory sustained 
release for 12 h and the release was governed by swelling 
of the polymer followed by drug diffusion through the 
swollen polymer and slow erosion of the beads.
Lemieux, Gosselin and Mateescu (2015) prepared 
microspheres from carboxymethyl starch powder and 
investigated the influence of degree of substitution 
(0.1 to 1.5) on the physicochemical, drug release and 
mucoadhesion properties as well as interactions with 
gastrointestinal tract epithelial barrier models. Placebo 
and furosemide loaded microspheres were obtained by 
emulsion-crosslinking with sodium trimetaphosphate. 
The degree of substitution impacted the equilibrium 
water uptake and modulated drug release properties of the 
microspheres according to the surrounding pH. The drug 
release, permeability enhancement and mucoadhesive 
properties of the microspheres suggested that the 
microspheres made with carboxymethyl starch powder 
with degree of substitution between 0.6 and 1.0, were 
suitable excipient for GRDDS.
Using isabgol as an excipient for developing 
GRDDS of lisinopril was experimented by Semwal, 
Semwal and Semwal (2014) and its gastroretentive ability 
was enhanced by addition of sodium bicarbonate as a gas-
generating agent while its mucoadhesive property was 
enhanced by incorporation of HPMC K4M. The drug, 
sodium bicarbonate and HPMC K4M were imbibed on 
isabgol husk, dried and filled in a hard gelatin capsule. 
The drug released through isabgol was delayed by 12 h 
in comparison to commercially available formulation of 
lisinopril which released the drug completely in 0.5 h. 
The drug release study from the formulation followed first 
order kinetics using a diffusion controlled mechanism. 
The results from the present study concluded that isabgol 
can be used as a potential excipient for the formulation of 
GRDDS in future. 
Formulation of gastroretentable mucoadhesive 
patch of lercanidipine HCl has been reported by Pandey 
et al. (2013). The patch consisted of a rate controlling 
film (Eudragit RSPO and RLPO) and a mucoadhesive 
film of various hydrophilic polymers. The bilayered patch 
was prepared by using the layering method. The film was 
folded into a hard gelatin capsule and evaluated for in 
vitro drug release in pH 1.2 containing 0.2% (w/v) sodium 
lauryl sulphate, and in vivo bioavailability in rabbits. The 
patches showed controlled drug release up to 12 h and 
optimal mucoadhesion (4.05±0.4 to 4.52±0.12 N). In vivo 
bioavailability results revealed that the gastroretentive 
patch system provided a novel way to retain the drug 
matrix for the longer period of time in stomach, enhance 
drug absorption and thereby offer a promising strategy 
for gastroretentive mucoadhesive drug delivery for the 
lercanidipine HCl.
COMMERCIALIZATION AND PATENTS 
The commercial potential of GRDDS has already 
been proven. Commonly used drugs in formulation of 
gastroretentive dosage forms and the marketed products 
of antihypertensives available as GRDDS can be found 
in Table II and Table III respectively. While to the best of 
our knowledge only four products could be found, twice 
the number of patents was documented in literature as 
compiled in Table IV. This definitely offers wide vistas for 
researchers to explore the less trodden area. A few of the 
patents have been described briefly in the following text. 
Dudhara, Dharmadhikari and Dhayse (2004) 
patented a gastric retention controlled drug delivery system 
comprising: (a) a controlled release core comprising a 
drug, a highly swellable polymer and a gas generating 
agent, said core being capable of swelling and achieving 
floatation rapidly while maintaining its physical integrity 
in gastrointestinal fluids for prolonged periods and (b) 
a rapidly releasing coat so that the system provides a 
biphasic release of the drug in gastrointestinal fluids.
Ogorka et al. (2009) has been assigned a patent for 
an extended release GRDDS of valsartan containing a 
release portion of valsartan, a gastroretentive portion for 
retaining the drug delivery system in the stomach and an 
optional secondary portion for delivering a secondary 
pulse of valsartan. In another embodiment, a swellable 
unfolding membrane comprising Valsartan for sustained 
administration of Valsartan has been provided to the upper 
GI tract of a patient.
Mullen, Stevens and Eccleston (2011) got patented 
an invention in which an active agent is designed to be 
released in a prolonged manner at a point of time some 
time after administration of the active agent. The present 
invention is particularly suitable for administering an 
agent that may be released while the subject is sleeping, 
shortly before waking up and continues to administer 
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TABLE II - Summarized compilation of antihypertensive drugs explored for various GRDDS
Dosage forms Antihypertensive drugs
Tablets Losartan (Chen, 2010), propranolol (Chinta, Graves, Pamujula, 2009; Srikanth et al., 2012), furosemide 
(Ozdemir, Ordu, Ozkan, 2000; Sahu, Singh, Verma, 2011), verapamil (Elkheshen, Yassin, 2004; Sawicki, 
2002), captopril (Martinez, Ramirez, Robles, 2010; Nur, Zhang, 2000), nimodipine (Barmpalexis, 
Kachrimanis, Georgarakis, 2011; Wu et al., 1997), nicorandil (Nath, Ahmed, 2016), quinapril (Mali, Bathe, 
2015), amlodipine (Ramasubramaniyan et al., 2015), atenolol (Charan, Meher, Pochaiah, 2013), metoprolol 
(Ratnaparkhi, Garje, Chaudhari, 2013)
Microspheres Lacidipine (Sultana et al., 2009), diltiazem (Ma et al., 2008), propranolol (Adebisi, Conway, 2011; Patel 
et al., 2006), furosemide (Iannuccelli et al., 2000), verapamil (Tanwar, Naruka, Ojha, 2008), nifedipine 
(Soppimath et al., 2006), carvedilol (Zhang et al., 2016)
Capsules Nicardipine (Moursy et al., 2003), lisinopril (Semwal’s, 2014), lercanidipine (Pandey et al., 2013)
Granules Diltiazem (Shimpi et al., 2004)
Films Furosemide (Darandale, Vavia, 2012), captopril (Sathish et al., 2013; Pathak, Mishra, 2013)
Beads Diltiazem (Saxena et al., 2016), furosemide (ElMeshad, El-Ashmoony, 2012), verapamil (Eldeen, Alsara, 
Mohizea, 2006), captopril (Pawar, Lalitha, Ruckmani, 2015)
TABLE III - Marketed products of GRDDS for antihypertensive drugs (Srikanth, 2011; Awasthi, Kulkarni, 2016)
Drug Technology Brand name Manufacturer
Prazosin HCl Effervescence and swelling 
based floating system.
Prazopress XL® Sun Pharma, India
Carvedilol Osmotic system Coreg CR® Glaxosmithkline, USA
Verapamil HCl OROS Covera HS® DURECT Corporation, USA
Nisoldipine GeomatrixTM Sular® Skyepharma, Shionogi Pharma Inc. UK
the drug during the early waking hours. The invention 
treats certain conditions by a particular regime, as well as 
provides novel formulations for a delayed, followed by a 
prolonged release of drug.
FUTURE PERSPECTIVE
A controlled drug delivery system with prolonged 
residence time in the stomach can be of great importance 
for antihypertensive drugs with select pharmacokinetic 
features. The systems developed include gastroretentive 
tablets, capsules, microspheres, granules and beads. 
Many other systems can be explored for developing 
GRDDS of antihypertensive drugs. These may be 
osmotically regulated systems that offer the possibility of 
varying the formulation variables and exploring various 
designs. Unfolding bilayer system, raft based and ion 
exchange resin systems may be utilized depending upon 
the physicochemical properties of the drug. The bilayer 
unfolding and raft forming systems need to be explored 
extensively as scarce reports can be found in literature that 
offer most promising GRDDS. Through bilayer unfolding 
systems both sustained as well as immediate release can 
be obtained, and sustained release can be increased up to 
24 h. At the same time, small size of the folded system 
makes it easy to administer and on reaching the stomach it 
will unfold and swell to prolong gastric retention thereby 
increasing gastric emptying time as well as increasing 
bioavailability. More research is required on this system 
that has potential for exhibiting excellent results in 
controlling hypertension.
The ion-exchange resin complexes can be prepared 
from both acidic and basic drugs and have immense 
commercial potential. Salts of cationic and anionic 
exchange resins are insoluble complexes in which drug 
releases from exchange of bound drug ions by ions 
normally present in body fluids; in this case the gastric 
fluid (Guo, Chang, Hussain, 2009). However, judicious 
selection of the ion-exchange resins and the drug are of 
utmost importance. Another significant system that has 
been reported for its gastroretentivity is based on floatation 
and is microsponges. In a report by Arya and Pathak (Arya, 
Pathak, 2014), the viability of microsponges as GRDDS 
was assessed in delivering curcumin for the treatment 
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of gastric cancer. The in vitro permeation capability 
of curcumin along with favourable pharmaceutical 
and pharmacokinetic characteristics of the optimized 
formulation affirmed the capability of microsponges as 
efficient GRDDS. 
Over the last few decades majority of the work 
was done on the GRDDS of antihypertensives reports 
development of novel systems by using single drug. 
Clinically, for chronic hypertensive cases, dual drug 
therapy is advised that presents a new area of research 
TABLE IV - Patents on grdds of antihypertensive drugs
Patent/Application number 
(year of issue/publication) & 
Drug
Original assignee/
Applicant Comment Ref.
US20040180088A1 
(2004) 
Antihypertensives
Dudhara KM, 
Dharmadhikari NB, 
Dhayse VV.
Provides a gastric retention controlled drug 
delivery system comprising: (a) a controlled 
release core comprising a drug, and (b) a 
rapidly releasing coat so that the system 
provides a biphasic release of the drug in 
gastrointestinal fluids.
(Dudhara, 
Dharmadhikari, 
Dhayse, 2004)
EP2061438 A1 (2009) 
Valsartan Novartis AG
Invented an extended release GRDDS 
of valsartan containing a release portion 
of  valsartan, a gastroretentive portion for 
retaining the drug delivery system in the 
stomach and an optional secondary portion 
for delivering a secondary pulse of valsartan.
(Ogorka et al., 2009)
WO2009087665 A2 (2009) 
Propranolol Vishwanath SN
Claimed a novel GRDDS that floats over the 
simulated physiological fluids owing to its 
low density. The system comprises inert core, 
polymers and plasticizer. 
(Vishwanath, 2009)
US7776345 B2 (2010) 
Antihypertensives
Sun Pharma 
Advanced Research 
Company Ltd
A GRDDS comprising a controlled release 
core of the, a highly swellable polymer and 
a gas generating agent, and (b) a rapidly 
releasing coat such that the system provides 
a biphasic release of the drug.
(Dudhara, 
Dharmadhikari, 
Dhayse, 2010)
WO2011107750 A2 (2011) 
Antihypertensives
University of 
Strathclyde
Discloses an invention in which an active 
agent is designed to be released in a prolonged 
manner at a time point some time after 
administration of the active agent.
(Mullen, Stevens, 
Eccleston, 2011)
WO2013051036 A1 (2013) 
verapamil, propranolol,  
captopril, diltiazem
Council of Scientific 
& Industrial 
Research, 
India
The invention discloses a GRDDS comprising 
a drug in the core and coated with a coating 
of a pH sensitive polymer. The system 
can release the drug in both sustained and 
pulsatile manner.
(Kolhe, Kulkarni, 
2013)
WO2013054285 A1 (2013) 
ACE inhibitors
Ranbaxy Laboratories, 
New Delhi, India
Invented a floating capsule which releases the 
drug without any lag time and which remains 
buoyant for a sufficient period of time in the 
stomach. 
(Kumar, Ahmad, 
Singh, 2013)
US8586083 B2 (2013) 
Metoprolol Euro-Celtique S.A.
The invention is produced by extrusion. 
The use of extrusion enables the product to 
take many useful forms. The product may 
comprise a sheet of hydratable polymer, the 
hydrated sheet being of a size which will not 
pass out of the stomach, for example a shaped 
sheet or a roll.
(Mohammad, 2013)
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focussing on dual drug release systems. One can find few 
reports on drug delivery systems based on dual release 
mechanism and an interesting design has been reported 
recently by Rajput Singh and Pathak (2014) though not 
for antihypertensives. Briefly, the authors developed 
a bifunctional single unit capsular system comprising 
uniquely shaped gastroretentive fanicular cylindrical 
system for immediate release of granules of ranitidine 
HCl and controlled delivery of clarithromycin (Figure 3). 
The fanicular cylindrical system of clarithromycin 
exhibited synergistic gastroretention due to its floating 
and bioadhesive features. This system can be extrapolated/ 
modified version can serve as a lead for development of 
bifunctional /dual release systems of antihypertensive 
drugs.
CONCLUSION
Adequate control of the gastric residence time 
combined with controlled drug release patterns can 
significantly improve the bioavailability of the drug. 
To achieve this goal, floating, bioadhesive, expanding/
swelling and raft forming systems have depicted 
promising potential. However, various other systems 
need to be explored for achieving maximum therapeutic 
efficacy. While many systems have proven their efficacy, 
in vitro and in vivo, clinical intricacies need to be resolved 
before the novel GRDDS can be put into commercial use.
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